M

Mass General Brigham

Early-stage life science venture investor

Patient Care Assistant Float Pool

Full-TimeUpdated on 10/23/2026
$18.56 - $27.58/hr+ Differentials + Premiums + Bonuses
Entry
Boston, MA, USA
In Person
Medical, Clinical & VeterinaryNursing & Frontline Patient Care

About the job

Requirements
  • A high school diploma or equivalent is required.
  • A Certified Nursing Assistant/Patient Care Technician credential and Heartsaver CPR/AED certification from the American Heart Association are required.
  • Successful completion of an approved nursing assistant training program is required.
  • Ability to speak, read, and write in English is required.
  • Ability to pass clinical competency, basic math, and reading tests is required.
  • Ability to perform basic math calculations and measurements for height, weight, intake and output, and calorie counts is required.
  • Ability to accurately interpret and use basic medical terminology and abbreviations is required.
  • Ability to enter and retrieve computerized information is required.
  • Physical ability to push, transfer, and pull heavy loads throughout the assigned shift is required.
  • Physical ability to meet core job requirements in accordance with practice-setting demands and the patient populations regularly served is required.
  • Interpersonal skills to interact appropriately with nursing staff, patients, families and visitors, physicians, and other hospital staff are required.
  • Organizational skills to set priorities and efficiently complete assigned work are required.
  • Ability to manage stress related to patient-care issues and changing hospital and personnel conditions is required.
  • Staff must adhere to the organization's I C.A.R.E. Standards.
Responsibilities
  • Anticipate and identify patient safety risks with the licensed nurse and take appropriate action to reduce or eliminate them, including maintaining bed height, using side rails and alarms appropriately, keeping call lights within reach, conducting frequent patient checks, and assisting with ambulation as indicated.
  • Make routine patient-room rounds to address patient needs.
  • Follow restraint policies under licensed-nurse supervision and consult the licensed nurse before using restraints.
  • Provide one-to-one observation for patients at risk for injury.
  • Follow hospital infection-control and safety procedures and use proper body mechanics when moving and assisting patients.
  • Maintain an atmosphere reflecting the organization's mission and values; support a culturally diverse staff and patient population; and provide nondiscriminatory care that respects patient diversity.
  • Maintain confidentiality and privacy of patient, employee, and hospital information.
  • Work cooperatively with staff and seek assistance from the RN, Nursing Director, or Nursing Supervisor to resolve interpersonal conflicts as needed.
  • Wear attire that meets dress-code requirements, including a visible hospital identification badge identifying the employee as a Patient Care Assistant.
  • Organize time and prioritize patient-care needs; work with other patient care assistants to facilitate care and assist coworkers as requested.
  • Adapt to changing patient and unit needs, including floating and adjusting assignments; coordinate breaks with the Charge Nurse or Nursing Supervisor; and notify the Charge Nurse or Staff Nurse before leaving the work area.
  • Review and understand relevant policies, procedures, and work rules; understand hospital emergency codes and how to call a code; use hospital email to access staff meeting minutes, notices, and memos; review clinical updates; and participate in staff meetings and in-services.
  • Communicate with the RN throughout the shift about patient condition and delegated tasks, and immediately report significant changes or monitoring alarms, including changes in vital signs or mental status, pain complaints, abnormal blood sugar, falls or injuries, and patient concerns.
  • Collect and accurately record patient data, including vital signs, intake and output, blood sugar, weights, and restraint care and monitoring, in accordance with hospital documentation standards.
  • Maintain a teamwork approach to patient care.
  • Address patient comfort and information needs with nonclinical information; orient patients and visitors to the hospital, unit, room services, and available items; distribute mail, flowers, and nourishment; keep personal-care items and call lights accessible; change linens and clothing; refill ice packs; and run patient errands as assigned by the RN.
  • Reinforce nurse-provided patient education in collaboration with the licensed nurse and provide basic instructions on call-light use, positioning, transferring, walking, toileting, and feeding.
  • Comply with practice standards, policies, procedures, protocols, guidelines, and regulations, including applicable Department of Public Health, Joint Commission, Boston fire-code, and Occupational Safety and Health Administration requirements; maintain hospital, nursing, unit, and technical competencies.
  • Maintain competence in technical skills such as applying external monitors, using a continuous passive motion machine, performing EKGs and blood glucose monitoring, applying simple dressings, and using Heartsaver CPR and AED skills.
  • Assist in orienting new patient care assistants and serve as a resource to float staff.
  • Participate in hospital-wide and unit-based SEAQ programs and activities as indicated, and communicate patient-care quality concerns to the Nursing Director, Nurse Director, Clinical Leader, or Nursing Supervisor.
  • Complete patient care assigned by the licensed nurse in accordance with hospital policy and procedure.
  • Assist with patient admission, discharge, and transfer; prepare rooms for admission; and ensure patients have appropriate identification bands during hospitalization.
  • Transport patients, belongings, equipment, and supplies as needed during transfer or discharge.
  • Provide personal care, including bathing, skin care, shaving, mouth care, grooming, perineal care, and changing linens, according to hospital protocols.
  • Provide basic skin care, including back rubs, routine diabetic foot care, non-medicated ointments, elastic stockings, ace wraps, compression boots, repositioning every two hours, and related tasks.
  • Assist with elimination, including urinary and condom catheter care, bedpan and commode use, toileting schedules, emptying colostomy bags, urinals, and urinary drainage bags.
  • Carry out planned comfort and pain-relief measures, including coordinating rest periods, minimizing noise, and assisting with bed positioning.
  • Provide one-to-one observation for patients at risk for injury while also performing PCA II duties for the assigned patient.
  • Perform simple dressing changes using aseptic technique and assist nurses or health-team members during simple and complex treatments or procedures.
  • Set up meals, assist with feeding and opening food containers, maintain calorie counts, and record intake and output.
  • Take and document patient vital signs, intake and output, and daily weights accurately and completely.
  • Perform EKGs and blood glucose monitoring as directed and in accordance with hospital and Nursing Department policies and procedures.
  • Document patient information accurately, completely, and on time on patient flow sheets.
  • Provide end-of-life care, including comfort measures and postmortem care.
  • Collect, label, and transport specimens to the laboratory with the appropriate requisitions.
  • Initiate patient belongings tracking forms and secure belongings according to hospital policy in coordination with the RN; consult the RN if the patient declines secure storage or sending belongings home with family or a friend.
  • Respond promptly and courteously to patient call lights and requests and seek coworker assistance as appropriate.
  • Keep patient rooms orderly and clean, stock rooms with needed supplies and equipment, and conduct rounds to clean and organize patient areas as needed.
  • Check inventories and restock, replace, or assemble patient equipment and supplies; dispose of trash, soiled linens, medical waste, and disposable items appropriately; and perform spot and spill cleaning as needed.
  • Check equipment regularly according to policy to ensure it operates properly and has current safety inspections and expiration dates before patient use; remove broken or expired equipment and supplies from service and notify the Charge RN or Staff Nurse.
  • Perform initial cleaning and decontamination of equipment and materials, including removing reusable equipment from isolation rooms, and arrange terminal cleaning as appropriate.
  • Identify emergency or crisis situations and initiate appropriate responses within role scope, immediately communicating events to the RN and assisting the nurse during and after emergencies as directed.

About the company

Mass General Brigham Ventures funds early-stage life science ideas arising from Mass General Brigham’s research network. It provides first access to deal flow and proprietary rights, backing the formation and growth of new companies and technologies. It uses capital and support to help translate bold innovations into drugs and medical technologies that improve patient outcomes worldwide.

Company Size

1-10

Company Stage

N/A

Total Funding

$1.9B

Headquarters

Cambridge, Massachusetts

Founded

2008

Get referred to Mass General Brigham

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Mass General Brigham reported $15 million operating income through June 30, 2026.
  • Outpatient growth and higher-acuity inpatient volumes drove 7% revenue growth in Q3 FY26.
  • Abcuro's 2026 financing extends a potential registrational trial, validating MGB Ventures sourcing.

What critics are saying

  • Brigham nurses authorized an indefinite strike on September 24, 2026; operations face disruption.
  • MGB refused negotiations after July strikes and lockouts, deepening staffing instability into 2027.
  • The September 2026 antidiscrimination case and website-data settlement reinforce litigation overhangs.

What makes Mass General Brigham unique

  • Mass General Brigham controls flagship Boston hospitals and a research-to-venture pipeline.
  • MGB Ventures backed Abcuro's $66 million Series D in August 2026.
  • Its $22.8 billion 2025 operating revenue funds clinical, academic, and commercialization depth.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • Flexible Work Hours
  • Remote Work Options
  • Hybrid Work Options
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Family Planning Benefits
  • Fertility Treatment Support

Company News

Business Wire
Oct 25th, 2026
Nocion Therapeutics Extends Series B Financing to $93 Million to Support Late-Stage Development of Taplucainium in Chronic Cough

Nocion Therapeutics, Inc. today announced that it has raised $23 million from existing investors in an extension of its Series B, bringing the total amount o...

PR Newswire
Oct 1st, 2026
Mass General Brigham postpones annual summit after nurses plan picket over $2.3B hospital system refusing fair contracts

Mass General Brigham has postponed its annual summit after nurses and clinicians represented by the Massachusetts Nurses Association issued a picket notice for the 7 October event in Somerville. The postponement follows a 93% strike authorisation vote by Brigham and Women's Hospital nurses and protests against MGB executives. MGB nurses and clinicians have been campaigning against the hospital system following strikes and a lockout in July. Brigham nurses are seeking contract improvements including limits on temporary nurses, affordable health insurance, and fair compensation. MGB Home Care clinicians are negotiating their first union contract. MGB reported $22.8 billion in operating revenue and $2.39 billion in profits for fiscal year 2025. The system has refused to return to negotiations since August.

ABCuro
Aug 18th, 2026
Abcuro announces $66 million Series D financing to advance its first-in-class Medicine in development for Inclusion Body Myositis.

Abcuro announces $66 million Series D financing to advance its first-in-class Medicine in development for Inclusion Body Myositis. * Proceeds to support a potentially registrational clinical study in less severe inclusion body myositis (IBM) patients expected to begin in Q4 2026 and report top line results in 2H 2028 * Ulviprubart showed a trend toward clinically meaningful slowing of disease progression in patients with less severe IBM in the previous Phase 2/3 MUSCLE study * Series D financing led by New Leaf Venture Partners, joined by Abcuro's existing investors and new investor Rock Springs Capital Newton, Massachusetts, August 18, 2026 - Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases through precise modulation of cytotoxic T cells, today announced the closing of a $66 million Series D financing led by current investor New Leaf Venture Partners with participation of existing investors including funds managed by abrdn Inc., Bain Capital Life Sciences, Samsara BioCapital, Redmile Group, Mass General Brigham Ventures, RA Capital Management, Pontifax, Sanofi Ventures, Foresite Capital, NEA, Eurofarma Ventures, Kaitai Capital, Soleus Capital, Nancy Chang, Shang Bay and joining the round is Rock Springs Capital. Proceeds from the Series D financing will support a new potentially registrational clinical study of ulviprubart, a first-in-class monoclonal antibody targeting killer cell lectin like receptor G1 (KLRG1), for the treatment of patients with less severe IBM. Abcuro has been in discussions with the U.S. Food and Drug Administration (FDA) and expects to initiate the new study in the fourth quarter of this year. Assuming positive results from the clinical study, Abcuro plans to file a biologics license application (BLA). "We are pleased to have this opportunity to further evaluate ulviprubart in patients with IBM, a devastating progressive disease," said Alex Martin, Chief Executive Officer of Abcuro. "We have begun preparations to initiate a clinical trial in the fourth quarter of 2026 as we continue our work to develop an effective treatment option in an indication where there is no approved therapy. We remain dedicated to the IBM community and thank our investors who share our conviction in ulviprubart's potential." Results from the recent Phase 2/3 MUSCLE study of ulviprubart in patients with IBM were presented at the 6th Global Conference on Myositis (GCOM) meeting in March 2026. The clinical data, while not statistically significant, showed a trend toward slowing of disease progression relative to placebo as measured by IBMFRS in the overall patient population, including a 50% slowing of disease progression in a pre-defined analysis of less severe IBM patients with IBMFRS >29. Ulviprubart was also shown to have a favorable safety and tolerability profile compared to placebo. "The MUSCLE study provided encouraging data in a pre-defined analysis of patients with less severe disease, underscoring ulviprubart's unique mechanism of targeting highly differentiated cytotoxic T cells expressing KLRG1," said Namita Goyal, MD, Chief of the Neuromuscular Division at the University of California, Irvine School of Medicine. "IBM continues to be a disabling, progressive disease with no approved treatment, affecting tens of thousands of patients around the world. Ulviprubart demonstrated clear and meaningful slowing of disease progression in less severe disease, offering real hope to patients, care partners, and the physicians who treat them." "There is a significant unmet need for an approved treatment for IBM. The expertise and persistence of the Abcuro team to understand this disease and the role ulviprubart may have in targeting these cytotoxic T cells that are associated with muscle destruction was key to our continued investment of the company. We are excited to work closely with the company as it moves forward in this next chapter," said Ron Hunt, Co-Founder and Managing Director of New Leaf Venture Partners. About Ulviprubart Ulviprubart is a first-in-class, potent, monoclonal antibody that targets pathogenic T cells that express killer cell lectin-like receptor G1 (KLRG1) on their cell surface, referred to as KLRG1+ T cells. Ulviprubart is designed to selectively target and deplete well-differentiated cytotoxic KLRG1+ T cells where KLRG1 is highly expressed, while sparing other immune cells, which may offer improvements in safety and tolerability as compared to other T cell depleting approaches. About Inclusion Body Myositis (IBM) IBM is a rare, debilitating and relentlessly progressive chronic autoimmune muscle disease with no approved pharmacologic treatments and a significant unmet need. It is mediated by highly differentiated T cells that are chronically or aberrantly overstimulated and can have detrimental long-term effects including destruction of healthy muscle tissue. People living with IBM progressively lose muscle function, including loss of grip, dexterity and mobility. Based on published epidemiology literature, the ICD-10 code for IBM and an estimate for those misdiagnosed or undiagnosed, Abcuro estimate there are approximately 40,000 patients diagnosed with IBM in the United States and Abcuro estimate the prevalence of IBM to be approximately 35,000 patients across major European countries and Japan. Abcuro estimate that patients with less severe disease represent nearly 50% of the overall IBM patient population. About Abcuro Abcuro is a clinical stage biotechnology company developing potentially first-in-class immunotherapies designed to benefit people living with debilitating and progressive rare autoimmune diseases and for other indications where certain cytotoxic T cells are pathogenic. Abcuro believe that by selectively targeting and depleting highly cytotoxic T cells, which are key drivers of chronic inflammation and damage, Abcuro can advance its mission to deliver potentially life-transforming, disease-modifying therapies to patients facing these devastating conditions. The company's lead program, ulviprubart, is currently being evaluated in inclusion body myositis (IBM). For more information, visit Abcuro on LinkedIn and at abcuro.com.

Claris Bio
Jul 29th, 2026
07-28-2026 Press Releases from Claris Bio

Latest Press Releases from Claris Bio.

Fierce Healthcare
Jun 15th, 2026
InStride Health lands $30M series C to expand pediatric mental health services

InStride Health, a provider of virtual specialty mental healthcare for children and young adults, has raised $30 million in Series C funding led by Echo Health Ventures and FMZ Ventures. Existing investors including .406 Ventures, General Catalyst and Mass General Brigham Ventures also participated. Founded in 2021, InStride offers insurance-based treatment for anxiety and obsessive-compulsive disorder in patients aged seven to 24. The company pairs each patient with a care team comprising a psychiatrist, therapist and exposure coach, providing support through text and a mobile application. InStride has treated 5,000 patients across 17 states, primarily on the East Coast and Texas. The company published data showing 97% of patients demonstrated clinical improvement, with a 53% average reduction in anxiety scores. The funding will support expansion into new markets and strengthen payer partnerships.